Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Predicting hospital admission at the emergency department triage: A novel prediction model.

Parker CA, Liu N, Wu SX, Shen Y, Lam SSW, Ong MEH.

Am J Emerg Med. 2018 Oct 29. pii: S0735-6757(18)30891-X. doi: 10.1016/j.ajem.2018.10.060. [Epub ahead of print]

PMID:
30413365
2.

First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site.

Venkataraman AV, Keat N, Myers JF, Turton S, Mick I, Gunn RN, Rabiner EA, Passchier J, Parker CA, Tyacke RJ, Nutt DJ.

EJNMMI Res. 2018 Jul 30;8(1):71. doi: 10.1186/s13550-018-0429-x.

3.

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT.

JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.

4.

Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain.

Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, Husbands SM, Rabiner EA, Gunn RN, Murphy PS, Parker CA, Nutt DJ.

J Nucl Med. 2018 Oct;59(10):1597-1602. doi: 10.2967/jnumed.118.208009. Epub 2018 Mar 9.

5.

A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ6.

Keat N, Kenny J, Chen K, Onega M, Garman N, Slack RJ, Parker CA, Lumbers RT, Hallett W, Saleem A, Passchier J, Lukey PT.

J Nucl Med Technol. 2018 Jun;46(2):136-143. doi: 10.2967/jnmt.117.203547. Epub 2018 Feb 2.

6.

Torpor and basking after a severe wildfire: mammalian survival strategies in a scorched landscape.

Matthews JK, Stawski C, Körtner G, Parker CA, Geiser F.

J Comp Physiol B. 2017 Feb;187(2):385-393. doi: 10.1007/s00360-016-1039-4. Epub 2016 Oct 12.

PMID:
27734149
7.

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.

Irving JA, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV.

Blood. 2016 Aug 18;128(7):911-22. doi: 10.1182/blood-2016-03-704973. Epub 2016 May 26.

8.

Identification of potent and selective MTH1 inhibitors.

Petrocchi A, Leo E, Reyna NJ, Hamilton MM, Shi X, Parker CA, Mseeh F, Bardenhagen JP, Leonard P, Cross JB, Huang S, Jiang Y, Cardozo M, Draetta G, Marszalek JR, Toniatti C, Jones P, Lewis RT.

Bioorg Med Chem Lett. 2016 Mar 15;26(6):1503-1507. doi: 10.1016/j.bmcl.2016.02.026. Epub 2016 Feb 11.

PMID:
26898335
9.

EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.

Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ.

Blood. 2016 May 5;127(18):2214-8. doi: 10.1182/blood-2015-09-670166. Epub 2016 Feb 12.

10.

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.

Cheraghchi-Bashi A, Parker CA, Curry E, Salazar JF, Gungor H, Saleem A, Cunnea P, Rama N, Salinas C, Mills GB, Morris SR, Kumar R, Gabra H, Stronach EA.

Oncotarget. 2015 Dec 8;6(39):41736-49. doi: 10.18632/oncotarget.6153.

11.

Human Kinetic Modeling of the 5HT6 PET Radioligand 11C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease.

Parker CA, Rabiner EA, Gunn RN, Searle G, Martarello L, Comley RA, Davy M, Wilson AA, Houle S, Mizrahi R, Laruelle M, Cunningham VJ.

J Nucl Med. 2015 Dec;56(12):1901-9. doi: 10.2967/jnumed.115.162743. Epub 2015 Sep 17.

12.

Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial.

Masurekar AN, Parker CA, Shanyinde M, Moorman AV, Hancock JP, Sutton R, Ancliff PJ, Morgan M, Goulden NJ, Fraser C, Hoogerbrugge PM, Revesz T, Darbyshire PJ, Krishnan S, Love SB, Saha V.

PLoS One. 2014 Oct 3;9(10):e108107. doi: 10.1371/journal.pone.0108107. eCollection 2014.

13.

Imaging endogenous opioid peptide release with [11C]carfentanil and [3H]diprenorphine: influence of agonist-induced internalization.

Quelch DR, Katsouri L, Nutt DJ, Parker CA, Tyacke RJ.

J Cereb Blood Flow Metab. 2014 Oct;34(10):1604-12. doi: 10.1038/jcbfm.2014.117. Epub 2014 Jul 9.

14.

The influence of different cellular environments on PET radioligand binding: an application to D2/3-dopamine receptor imaging.

Quelch DR, Withey SL, Nutt DJ, Tyacke RJ, Parker CA.

Neuropharmacology. 2014 Oct;85:305-13. doi: 10.1016/j.neuropharm.2014.05.040. Epub 2014 Jun 6.

15.

Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain.

Parker CA, Nabulsi N, Holden D, Lin SF, Cass T, Labaree D, Kealey S, Gee AD, Husbands SM, Quelch D, Carson RE, Nutt DJ, Huang Y, Tyacke RJ.

J Nucl Med. 2014 May;55(5):838-44. doi: 10.2967/jnumed.113.131854. Epub 2014 Apr 7.

16.

Sleep duration predicts cardiometabolic risk in obese adolescents.

Iglayreger HB, Peterson MD, Liu D, Parker CA, Woolford SJ, Sallinen Gafka BJ, Hassan F, Gordon PM.

J Pediatr. 2014 May;164(5):1085-1090.e1. doi: 10.1016/j.jpeds.2014.01.034. Epub 2014 Mar 6.

17.

Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies?

Kalk NJ, Owen DR, Tyacke RJ, Reynolds R, Rabiner EA, Lingford-Hughes AR, Parker CA.

Synapse. 2013 Dec;67(12):909-12. doi: 10.1002/syn.21681. Epub 2013 Jun 8. No abstract available.

PMID:
23666806
18.

Imaging imidazoline-I2 binding sites in porcine brain using 11C-BU99008.

Kealey S, Turner EM, Husbands SM, Salinas CA, Jakobsen S, Tyacke RJ, Nutt DJ, Parker CA, Gee AD.

J Nucl Med. 2013 Jan;54(1):139-44. doi: 10.2967/jnumed.112.108258. Epub 2012 Dec 5.

19.

Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.

Gieling RG, Parker CA, De Costa LA, Robertson N, Harris AL, Stratford IJ, Williams KJ.

J Enzyme Inhib Med Chem. 2013 Apr;28(2):360-9. doi: 10.3109/14756366.2012.736979. Epub 2012 Nov 19.

PMID:
23163664
20.

Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.

Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM.

Mol Cancer Ther. 2012 Nov;11(11):2526-34. doi: 10.1158/1535-7163.MCT-12-0460. Epub 2012 Sep 12.

21.

Influence of different cellular environments on [(3)H]DASB radioligand binding.

Quelch DR, Parker CA, Nutt DJ, Tyacke RJ, Erritzoe D.

Synapse. 2012 Dec;66(12):1035-9. doi: 10.1002/syn.21605. Epub 2012 Sep 20. No abstract available.

PMID:
22927261
22.

Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline₂ binding site.

Tyacke RJ, Fisher A, Robinson ES, Grundt P, Turner EM, Husbands SM, Hudson AL, Parker CA, Nutt DJ.

Synapse. 2012 Jun;66(6):542-51. doi: 10.1002/syn.21541. Epub 2012 Feb 22.

PMID:
22290740
23.

Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs.

Gunn RN, Summerfield SG, Salinas CA, Read KD, Guo Q, Searle GE, Parker CA, Jeffrey P, Laruelle M.

J Cereb Blood Flow Metab. 2012 May;32(5):874-83. doi: 10.1038/jcbfm.2012.1. Epub 2012 Jan 25.

24.

Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor.

Parker CA, Gunn RN, Rabiner EA, Slifstein M, Comley R, Salinas C, Johnson CN, Jakobsen S, Houle S, Laruelle M, Cunningham VJ, Martarello L.

J Nucl Med. 2012 Feb;53(2):295-303. doi: 10.2967/jnumed.111.093419. Epub 2012 Jan 5.

25.

An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28.

Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR, Mooser VE, Matthews PM, Rabiner EA, Rubio JP.

J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5. doi: 10.1038/jcbfm.2011.147. Epub 2011 Oct 19.

26.

Mixed-affinity binding in humans with 18-kDa translocator protein ligands.

Owen DR, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, Innis RB, Pike VW, Reynolds R, Matthews PM, Parker CA.

J Nucl Med. 2011 Jan;52(1):24-32. doi: 10.2967/jnumed.110.079459. Epub 2010 Dec 13.

27.

Evaluation of novel N1-methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligands.

Pike VW, Taliani S, Lohith TG, Owen DR, Pugliesi I, Da Pozzo E, Hong J, Zoghbi SS, Gunn RN, Parker CA, Rabiner EA, Fujita M, Innis RB, Martini C, Da Settimo F.

J Med Chem. 2011 Jan 13;54(1):366-73. doi: 10.1021/jm101230g. Epub 2010 Dec 6.

28.

Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain.

Owen DR, Lewis AJ, Reynolds R, Rupprecht R, Eser D, Wilkins MR, Bennacef I, Nutt DJ, Parker CA.

Synapse. 2011 Mar;65(3):257-9. doi: 10.1002/syn.20884. No abstract available.

PMID:
21132812
29.

Metastatic neuroblastoma to the mandible: an unusual presentation.

Parker CA, Liess BD, Gov-Ari E, Sramek BW.

Am J Otolaryngol. 2011 Sep-Oct;32(5):438-40. doi: 10.1016/j.amjoto.2010.07.015. Epub 2010 Sep 20.

PMID:
20851501
30.

Modulation of apoptosis: new opportunities for drug discovery to treat autoimmune thyroiditis.

Fang Y, Zhao L, Parker CA, Yan F, Zhang C.

Recent Pat Inflamm Allergy Drug Discov. 2010 Nov;4(3):255-60.

PMID:
20673222
31.

Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation.

Owen DR, Howell OW, Tang SP, Wells LA, Bennacef I, Bergstrom M, Gunn RN, Rabiner EA, Wilkins MR, Reynolds R, Matthews PM, Parker CA.

J Cereb Blood Flow Metab. 2010 Sep;30(9):1608-18. doi: 10.1038/jcbfm.2010.63. Epub 2010 Apr 28.

32.

Metastatic esophageal adenocarcinoma presenting as an external auditory canal mass.

Lollar KW, Parker CA, Liess BD, Wieberg J.

Otolaryngol Head Neck Surg. 2010 Feb;142(2):298-9. doi: 10.1016/j.otohns.2009.07.017. Epub 2009 Sep 26. No abstract available.

PMID:
20115997
33.

Using membrane stress to our advantage.

Shearman GC, Attard GS, Hunt AN, Jackowski S, Baciu M, Sebai SC, Mulet X, Clarke JA, Law RV, Plisson C, Parker CA, Gee A, Ces O, Templer RH.

Biochem Soc Trans. 2007 Jun;35(Pt 3):498-501. Review.

PMID:
17511638
34.

Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone.

Ellis CN, Barker JN, Haig AE, Parker CA, Daly S, Jayawardene DA; Avandia Psoriasis Study Group.

Am J Clin Dermatol. 2007;8(2):93-102.

PMID:
17428114
35.

From theory to practice: what drives the core business of public health?

Smith TA, Minyard KJ, Parker CA, Van Valkenburg RF, Shoemaker JA.

J Public Health Manag Pract. 2007 Mar-Apr;13(2):169-72.

PMID:
17299321
37.

Degradative transport of cationic amphiphilic drugs across phospholipid bilayers.

Baciu M, Sebai SC, Ces O, Mulet X, Clarke JA, Shearman GC, Law RV, Templer RH, Plisson C, Parker CA, Gee A.

Philos Trans A Math Phys Eng Sci. 2006 Oct 15;364(1847):2597-614.

PMID:
16973478
38.

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.

Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH.

Cancer. 2006 Jun 1;106(11):2437-44.

39.

Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia?

Williams KJ, Parker CA, Stratford IJ.

Adv Exp Med Biol. 2005;566:285-94. Review.

PMID:
16594164
40.

Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.

Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, Parker CA, Stratford IJ, Williams KJ.

Mol Pharmacol. 2006 Feb;69(2):411-8. Epub 2005 Oct 27.

PMID:
16254058
41.

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J.

J Clin Oncol. 2005 Dec 10;23(35):8968-77. Epub 2005 Oct 3.

PMID:
16204013
42.

Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4.

Parker CA, Matthews JC, Gunn RN, Martarello L, Cunningham VJ, Dommett D, Knibb ST, Bender D, Jakobsen S, Brown J, Gee AD.

Synapse. 2005 Mar 15;55(4):270-9.

PMID:
15668983
43.

PET studies in drug development: Methodological considerations.

Cunningham VJ, Parker CA, Rabiner EA, Gee AD, Gunn RN.

Drug Discov Today Technol. 2005 Winter;2(4):311-5. doi: 10.1016/j.ddtec.2005.11.003.

PMID:
24982006
44.

Harmane and harmalan are bioactive components of classical clonidine-displacing substance.

Parker CA, Anderson NJ, Robinson ES, Price R, Tyacke RJ, Husbands SM, Dillon MP, Eglen RM, Hudson AL, Nutt DJ, Crump MP, Crosby J.

Biochemistry. 2004 Dec 28;43(51):16385-92.

PMID:
15610033
45.

Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.

Yao J, Petanceska SS, Montine TJ, Holtzman DM, Schmidt SD, Parker CA, Callahan MJ, Lipinski WJ, Bisgaier CL, Turner BA, Nixon RA, Martins RN, Ouimet C, Smith JD, Davies P, Laska E, Ehrlich ME, Walker LC, Mathews PM, Gandy S.

J Neurochem. 2004 Aug;90(4):1011-8.

46.

Comparative effects of efaroxan and beta-carbolines on the secretory activity of rodent and human beta cells.

Morgan NG, Cooper EJ, Squires PE, Hills CE, Parker CA, Hudson AL.

Ann N Y Acad Sci. 2003 Dec;1009:167-74.

PMID:
15028583
47.

Effects of the beta-carbolines, harmane and pinoline, on insulin secretion from isolated human islets of Langerhans.

Cooper EJ, Hudson AL, Parker CA, Morgan NG.

Eur J Pharmacol. 2003 Dec 15;482(1-3):189-96.

PMID:
14660022
48.

Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study.

Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, Parker CA; Multinational Study Group.

BMJ. 2003 Jun 21;326(7403):1367.

49.

The incidence of positive cultures in women suspected of having PID/Salpingitis

Parker CA, Topinka MA.

Acad Emerg Med. 2000 Oct;7(10):1170.

50.

Isolation of RP-HPLC pure clonidine-displacing substance from NG108-15 cells.

Parker CA, Hudson AL, Nutt DJ, Dillon MP, Eglen RM, Crosby J.

Eur J Pharmacol. 2000 Jan 3;387(1):27-30.

PMID:
10633156

Supplemental Content

Loading ...
Support Center